The latest trading day saw Gilead Sciences (GILD) settling at $106.67, representing a -0.38% change from its previous close.…
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $105.87, denoting a -1.53% change from the…
Gilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash…
Charlotte (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse der Bank of America (BofA):
1. Einleitung
Die BofA hat ihre "buy"-Einstufung für die Aktie von Gilead…
These are the stocks posting the largest moves in midday trading.…
These are the stocks posting the largest moves in premarket trading.…
New York (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von Oppenheimer:
1. Hintergrund der Einschätzung
Oppenheimer hat die "outperform"-Bewertung für die Aktie von Gilead Sciences…
The Sun was shining brightly on the U.S. stock market over the past couple of years. Unfortunately, some clouds have…
Die beiden Gesellschaften Gilead Sciences und GSK (vormals GlaxoSmithKline) sind die führenden großen Anbieter von HIV-Medikamenten. Doch in den USA…
Gilead Sciences hits a 52-week high buoyed by investor optimism. We believe there is still room for growth and recommend…
Exelon, Gilead Sciences, Plains All American Pipeline, Sportradar and Cintas are part of the Zacks top Analyst Blog…
Gilead Sciences data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the drug.…
In 2024, technology stocks involved in artificial intelligence (AI) led the Nasdaq-100 index higher, while healthcare stocks struggled due in…
Despite recent negativity, several stocks, including Verizon Communications, Gilead Sciences, and Alibaba, have shaken off the woes, showing stability and…
Gilead Sciences and Johnson & Johnson are part of the Zacks Investment Ideas article.…
Here is how Gilead Sciences (GILD) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this…
Medical pioneer Gilead Sciences (GILD) has seen its stock etch out new 52-week highs as the broader market pulled back…
Bad Marienberg (www.aktiencheck.de) - Welche Kursziele und Ratings trauen die Analysten der führenden Banken und Research-Häuser der Aktie des biopharmazeutischen…
New York (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von Oppenheimer:
Die Analysten von Oppenheimer haben ihr Kursziel für Gilead Sciences Inc. (ISIN: US3755581036,…
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $115.99, denoting a +1.47% change from the…
…
Todays Research Daily features new research reports on 16 major stocks, including The Charles Schwab Corporation (SCHW), Gilead Sciences, Inc.…
Biotech giant Renegeron Pharmaceuticals (NASDAQ: REGN) reported its fourth-quarter and full-year 2024 earnings on Feb. 4. The companys results were…
Gilead (GILD) is at a 52-week high, but can investors hope for more gains in the future? We take a…
Shares of Gilead Sciences (NASDAQ: GILD) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after…
Kulmbach (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie…
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…
Der amerikanische Biotech-Riese Gilead Sciences hat im Schlussviertel 2024 überraschend stark abgeschnitten. Sowohl Umsatz als auch Ergebnis je Aktie lagen…
San Francisco (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von Wells Fargo Advisors:
Rating und Kursziel
Wells Fargo-Analyst Mohit Bansal hat das Kursziel für die…
…
GILD earnings call for the period ending December 31, 2024.…
…
…
Gilead Sciences Q4 earnings and sales beat estimates on higher HIV, oncology and liver disease drug sales. The stock is…
Gilead (GILD) delivered earnings and revenue surprises of 13.77% and 7.27%, respectively, for the quarter ended December 2024. Do the…
Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.…
Gilead Sciences posted fourth-quarter results that exceeded Wall Street estimates on Tuesday as its HIV drug sales rose 16% and…
…
Uber, Comcast, Gilead Sciences and Onfolio Holdings are included in this Analyst Blog.…
Foster City (www.aktiencheck.de) - Welche Kursziele und Ratings trauen die Analysten der führenden Banken und Research-Häuser der Aktie des biopharmazeutischen…
February is the shortest month, but that doesnt mean income investors dont have much time to find great stocks. Three…
Dividend stocks are great for many reasons, not least because any company that can sustain growing payouts for a long…
Todays Research Daily features new research reports on 16 major stocks, including Uber Technologies, Inc. (UBER), Comcast Corporation (CMCSA) and…
Artificial intelligence (AI) is transforming various industries as a major investing theme in 2025. The technologys ability to automate complex…
Gilead Sciences (GILD) closed at $99.65 in the latest trading session, marking a +1.69% move from the prior day.…
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.…
In the most recent trading session, Gilead Sciences (GILD) closed at $98.38, indicating a +1.21% shift from the previous trading…
…
Todays Research Daily features new research reports on 16 major stocks, including Salesforce, Inc. (CRM), Shell plc (SHEL) and Gilead…
Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gileads HIV prevention drugs Truvada and Descovy,…